These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38145840)

  • 1. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
    d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
    J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
    Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
    Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
    d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.
    d'Andrea G; Miuli A; Pettorruso M; Cavallotto C; Marrangone C; Cocco A; De Filippis S; Martiadis V; Andriola I; Barlati S; Vita A; Dell'Osso BM; Sensi SL; Di Lorenzo G; Martinotti G
    J Affect Disord; 2024 Dec; 367():583-588. PubMed ID: 39233241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
    Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
    [No Abstract]   [Full Text] [Related]  

  • 7. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
    Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
    Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
    Pettorruso M; Guidotti R; d'Andrea G; De Risio L; D'Andrea A; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; De Filippis S; Di Nicola M; Andriola I; Marcatili M; Nicolò G; Martiadis V; Bassetti R; Nucifora D; De Fazio P; Rosenblat JD; Clerici M; Maria Dell'Osso B; Vita A; Marzetti L; Sensi SL; Di Lorenzo G; McIntyre RS; Martinotti G;
    Psychiatry Res; 2023 Sep; 327():115378. PubMed ID: 37574600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
    Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
    Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
    J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
    Capuzzi E; Caldiroli A; Capellazzi M; Tagliabue I; Marcatili M; Colmegna F; Clerici M; Buoli M; Dakanalis A
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
    Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
    CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
    Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
    Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
    Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC
    J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609
    [No Abstract]   [Full Text] [Related]  

  • 20. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
    Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.